SPOTLIGHT: FDA rejects Glaxo depression drug

The FDA has turned thumbs down on GlaxoSmithKline's gepirone ER for major depression. Glaxo had licensed the drug from Fabre-Kramer after Akzo Nobel had bowed out of an earlier partnership. Analysts gave the drug some significant earnings potential, but have been wary of the drug's earlier problems with the FDA. Release